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INa: Na
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LV: left ventricle 
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ML: monolayer 
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RA: right atrium 
RA-CM: right atrial cardiomyocytes 
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RMP: resting membrane potential 
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STV: short-term variability 
STVRR: the short-term variability of the RR interval  
STVQT: the short-term QT-interval variability 
TdP: Torsades de pointes 
VcM: corrected membrane potential 
VmM: measured membrane potential 
VF: ventricular fibrillation 
VT: ventricular tachycardia 
WT: wild-type 
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3 Summary 
 
In cardiovascular research, there is a high need to use reliable tools for modelling 
cardiovascular diseases (LQT, LEOPARD, Andersen-Tawil syndrome) and for cardiovascular 
drug testing. It is necessary that those models reflect human heart physiology. The most 
commonly used models are human induced pluripotent stem cell-derived cardiomyocytes 
(hiPSC-CM) and transgenic animals, which showed promising results to study heart 
physiology. However, the existing hiPSC-CM and the animal models showed differences in 
electrophysiological properties due to immaturity and species differences. Therefore, it was of 
interest to study in detail the electrophysiological properties of the introduced models, hiPSC-
CM and a Long QT-syndrome type 5 (LQT5) transgenic (LQT5-TG) rabbit model. The major 
results described in this thesis can be summarized as follows: 
 
- When studying the electrophysiological profile of hiPSC-CM, one of the major 
concerns is the low inward rectifier potassium current (IK1) and resting membrane 
potential (RMP). In our study, hiPSC-CM were cultivated in two different conditions. 
One was the conventional monolayer (ML), while the other was Engineered Heart 
Tissues (EHT). In our hiPSC-CM cell line we were able to measure IK1 comparable to 
human adult cardiomyocytes (CM).  
- In contrast to previous publications, we were able to measure resting membrane 
potential (RMP) values in a physiological range using sharp microelectrode in intact 
EHT. We showed that the low RMP measured by patch electrodes may be prone to 
error. 
- Patch-clamp experiments on ventricular myocytes isolated from LQT5-TG rabbits 
were performed. The results showed differences in IKs and IKr deactivation kinetics. 
The deactivation kinetics of the currents were accelerated. 
- At baseline, LQT5-TG animals showed slightly, but signiﬁcantly prolonged heart-
rate corrected QT index (QTi) and increased STVQT. Dofetilide provoked Torsades de 
Pointes (TdP) arrhythmia in a larger number of LQT5-TG rabbits, paralleled by a 
further increase in short-term QT-interval variability (STVQT). 
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4 Introduction 
 
In public health, frequent occurrence of cardiac arrhythmias is a major concern. These 
arrhythmias can occur due to inherited diseases, (LQT, LEOPARD, Andersen-Tawil 
syndrome) or as a proarrhythmic effect of drugs, which can lead to ventricular 
tachycardia/ventricular fibrillation (VT/VF) [1–8]. “Arrhythmia” refers to any change in the 
normal sequence and/or shape of electrical impulses during the cardiac cycle. These are very 
important issues, and there is a high need to produce reliable models to study inherited heart 
diseases, as well as versatile tools for safety pharmacology.  
4.1 Challenges in the treatment of arrhythmias 
 
Antiarrhythmic drugs (AAD) can be categorized using the Vaughan Williams   4 – level 
schema or by the mechanistic and clinically relevant Sicilian Gambit. Some AAD have a 
complex action on the different ion channels, so they do not necessarily fit into any class of 
the Vaughan Williams classification schema [9]. The Sicilian Gambit classifies the agents 
based on their arrhythmogenic mechanism of action. This type of classification was 
introduced in 1991 [10,11]. 
Class I 
Drugs that delay fast sodium 
channel mediated conduction 
Class II 
Sympathetic  
antagonists 
 
 
Class III 
Drugs that 
prolong 
repolarisation 
Class IV 
Calcium 
antagonists 
 
IA 
Depress phase 0 
Delay conduction 
Prolong repolarisation 
Disopyramide, Procainamide, Quinidine 
 
IB 
Little effect on phase 0 in normal tissue 
Depress phase 0 in abnormal tissue 
Shorten repolarisation or little effect 
Diphenylhydantoin,  Lidocaine,  
Mexiletine, Tocainide 
 
IC 
Markedly depress phase 0 
Acebutolol 
Betaxolol 
Bisoprolol  
Bucindolol 
Carvedilol  
Esmolol  
Metoprolol  
Nadolol   
Propranolol 
Timolol 
Others 
 
Amiodarone 
Azimilide  
Bretylium   
Dofetilide   
Ibutilide   
Sotalol 
Tedisamil 
Diltiazem 
Verapamil 
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Markedly slow conduction 
Slight effect on repolarisation 
Flecainide, Moricizine, Propafenone 
 
Figure 1. The Vaughan Williams classification of antiarrhythmic drugs (adapted from [11] ). 
 
Drug treatment of cardiac arrhythmias still remains problematic, because of their 
inadequate effectiveness and a risk of serious complications, such as cardiac side effects. The 
physiological and pathophysiological mechanisms of cardiac arrhythmias are still unclear. 
Due to this, in many cases AAD have proarrhythmic effects. According to these problems, 
there is a high need to increase our understanding on the underlying mechanism of those 
cardiac arrhythmias both at the tissue and cellular level.  There is also a high need to develop 
new, safe and effective antiarrhythmic agents [12–14]. 
Several trials have been carried out to study the possible proarrhythmic effects of the 
existing antiarrhythmic agents, some studies showed increased mortality due to the side 
effects of the AAD. The Cardiac Arrhythmia Suppression Trial (CAST) investigated the 
effects of the existing AAD (Class I/C drugs encainide, flecainide) in patients with 
asymptomatic, or mildly symptomatic ventricular arrhythmia (six or more ventricular 
premature beats per hour), after myocardial infarction (Figure 2). The trial was designed to 
reveal, whether or not the antiarrhythmic agents can reduce the appearance of life threatening 
arrhythmias in patients with myocardial infarction. After 10 months of follow-up, the results 
showed an increased incidence of lethal cardiac arrhythmias in the drug-treated groups 
compared to the placebo. In conclusion, the use of encainide and flecainide was stopped in the 
trial, and these drugs were considered to be not safe enough anymore to treat patients with 
asymptomatic, or minimally 
symptomatic ventricular arrhythmia 
after myocardial infarction [7,8]. 
 
Figure 2. Higher rate of  survival  with  
placebo  compared  with  patients  taking 
encainide  or  flecainide  in  the  Cardiac  
Arrhythmia  Suppression Trial (CAST,     
adapted from [8]). 
 
 
 
In the meantime, the effects of the class III antiarrhythmic agent d-sotalol was 
investigated on mortality in high risk patients. The study was named SWORD (Survival With 
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Oral d-sotalol), and it revealed that administration of d-sotalol was associated with increased 
mortality, which was presumed primarily to be due to arrhythmias (Figure 3). The 
prophylactic use of the potassium channel blocker d-sotalol did not reduce mortality, and was 
associated with increased mortality in high-risk patients after myocardial infarction  [15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Survival curves with placebo and d-sotalol in the Survival With Oral d-sotalol study 
(SWORD, adapted from Waldo et al. 1996. [15]). 
 
4.2 The cardiac action potential and its underlying currents 
 
In the mammalian heart, the normal pump function critically depends on proper 
electrical function. The signal for contraction originates from specialized regions, where 
pacemaker cells are located. From those pacemaker regions the trigger propagates first 
through the atrial myocardium, transmitted by the atrio-ventricular node, enters the 
specialized excitation conduction system of the ventricles and finally spreads through the 
ventricular myocardium. Generation of action potentials are connected to this myocardial 
electrical activity of the individual cardiac cells, which can be also detected on surface 
electrocardiograms [16]. The APs are created by the organized activation and inactivation of 
ion channels that conduct depolarizing, inward (Na
+
 and Ca
2+
) and repolarizing, outward (K
+
) 
currents. The shape of the APs can differ in various different regions of the heart. These 
regional differences are due to the region-specific expression pattern of the cardiac ion 
channels, underlying the unidirectional propagation of the cardiac action potential, which is 
an essential requirement of maintaining  normal cardiac rhythm [17,18]. In the cardiac AP 
five different “phases”, are distinguished (Figure 4).  
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Transmembrane current 
200 ms 
Ik
1 
Ito 
IKr 
IKs 
ICa 
INa 
INCX 
INa/K 
(H)ERG, MIRP2 + MIRP3 
KvLQT1 + MinK + MIRP2 + MIRP3 
Kir 2.1, Kir2.2, Kir2.3, 
Kir2.4, TWIK1, TASK2 
Channel 
protein 
NCX
1 
Nav1.5, Nav1.7, Nav2.1,  
Cav1.2, Cav1.3 
Kv1.4, Kv1.7, Kv3.4, Kv4.2, Kv4.3, 
KCHIP2  
Na/K ATP-ase 
Phase 0 
Phase 1 Phase 2 
Phase 3 
Phase 4 
 
 
Figure 4. The ventricular action potential and corresponding ion currents. The upper panel shows a 
representative ventricular AP and phases of the AP kinetics. The underlying ionic currents are shown in the left 
side of the lower panel in time-match with the AP. The inward currents are depicted as downward deflections. It 
should be noted that the amplitudes of the currents are not proportional with each other. The channel proteins 
carrying the current are marked at right side of the lower panel (modified from [19]). 
 
The initial phase (phase 0) is the fast depolarization of the AP. During this phase the 
fast inward Na
+
 channels are activated. The sodium current (INa) has a relatively short-lived 
characteristic (2-3 ms), it creates a large charge influx to membrane depolarization. Beyond 
activating other currents of the AP (e.g.: Ca
2+
-current, K
+
-currents), this phase is responsible 
for the rapid impulse propagation. The phase 1 repolarization is determined by the transient 
outward potassium current (Ito). The kinetics of this current is similar to the INa, it is quickly 
activated and inactivated during depolarization, but is slower than the sodium current. The 
magnitude of this phase has an important role in shaping the spike-and-dome configuration of 
the AP. The expression level of Ito ion channel subunits can differ across the ventricular wall 
(and therefore the amplitude of Ito as well) [20], the spike-and-dome configuration can be 
considered a specific “marker” in identifying the epi-, myo, or endocardial origin of the cell. 
The phase 2 also called “plateau phase”, which is a typical property of the cardiac AP. During 
this phase the inward L-type calcium current (ICa,L) and outward potassium currents balance 
each other. They provide a long-lasting isoelectric phase, which has a crucial role in cell 
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contraction. ICa,L is an important player not only in shaping the action potential, but in 
initiation of intracellular Ca
2+
 cycle. When the ICa,L slowly inactivates, the outward K
+
 
currents are still active, and they start the late repolarization (phase 3). During the phase 3, the 
rapid and slow components of delayed rectifiers (IKr and IKs) support a relatively large, 
outward K
+
 current, having a crucial role in the repolarization. The inward rectifier K
+
 current 
(IK1) has a primary role to complete the final phase of the repolarization and stabilize a 
negative membrane potential. This phase 4 represents the resting membrane potential (RMP) 
during diastole. The RMP of the ventricular cardiomyocytes is determined by IK1 and possibly 
by the Na
+
/K
+
 pump and other background currents. In atrial and Purkinje cells, the 
expression level of IK1 is significantly smaller [21,22], the resting membrane potential is 
unstable and the depolarization is slow.  
4.3 The concept and role of the repolarization reserve 
 
In 1998, Dan M Roden introduced a concept, called repolarization reserve. This theory 
was based on clinical observations [23]. During phase 3, the AP is determined by a 
combination of four major repolarizing potassium currents including IKr, IKs, IK1 and Ito [24]. 
Based on clinical [23] and experimental data [24–26], it was observed in the mammalian 
ventricular muscle (human, dog and rabbit), the loss of one of the mentioned potassium 
currents does not necessarily cause APD prolongation. This is probably due to the capability 
of other potassium channels to compensate the loss of the activity of one K
+
 channel. Human, 
dog and rabbit ventricular myocytes seem to repolarize with a strong safety margin 
(“repolarization reserve”). This repolarization capacity is crucial to prevent life-threatening 
arrhythmias. If this mechanism is impaired by factors (cardiac and not cardiac as well), such 
as drug exposures, heart failure, diabetes mellitus, hypothyroidism, long QT syndromes, 
genetic diseases like Brugada-syndrome, etc, a minimal or moderate potassium current 
inhibition can result in dramatic and potentially proarrhythmic prolongation of the ventricular 
APD. Multiple K
+
 channel block can result in excessive repolarization lengthening by 
eliminating the repolarization reserve and therefore, it can be associated with increased 
proarrhythmic risk. 
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4.4 Models in cardiovascular pharmacology 
 
To understand better the mechanisms of arrhythmias and heart diseases, there is a high 
need to develop new models for this purpose. Differentiated hiPSC-CM from pluripotent stem 
cells provide a great opportunity to study human heart physiology and disease modelling. In 
several reports, hiPSC-CM cell-lines were successfully created, expressing cardiac ion 
channel mutations or hypertrophic cardiomyopathy [27–31]. These promising results open 
new avenues to establish personalized treatment options for individual patients, or repair the 
mutation using gene therapy techniques, such as CRISPR/Cas9 [32]. In the meantime, these 
cardiomyocytes were successfully used in high throughput systems as well [33]. The practical 
handling of hiPSC-CM brought them into a great attention as a novel, reliable tool for 
cardiovascular disease modelling and safety pharmacology. However, many studies reported 
that hiPSC-CM are immature and there are major differences in sarcomeric organization and 
electrophysiological properties, compared to human adult cardiomyocytes. Studies with patch 
clamp electrodes consistently reported RMP to be less negative in hiPSC-CM than in adult 
atrial or ventricular myocardium [29,34–38]. This is an alarming finding since correct RMP is 
mandatory for excitability and refractoriness. One of the possible explanations for a less 
negative RMP reported in hiPSC-CM is the absence or small amplitude of IK1. This  current is 
responsible for the stable, negative RMP in adult CM [39]. In line with this assumption, 
current densities of IK1 were reported to be low or almost absent in  hiPSC-CM cell lines 
[34,35,37]. Generation of Engineered Heart Tissues (EHT) from hiPSC-CM allows those CM 
to contract in a coupled manner and it showed progress in sarcomeric organization and 
contractile force [40]. The EHT format is suitable to use the sharp microelectrode technique to 
measure action potentials [41]. Whether EHT format favours maturation of hiPSC-CM in 
electrophysiological properties, such as IK1 current and RMP, remained unclear und was a 
subject of this thesis. 
Transgenic animals have been used as disease models, including cardiac diseases for a 
long time. Small rodents, such as mouse, provide a platform where the cardiomyocytes are 
mature, in vivo experiments can be done, and studies showed great results that those models 
expressing the mutant phenotype effectively, and it has really enlarged our knowledge about 
cardiac arrhythmia mechanisms [42,43]. However, the major problem with those models is 
that the electrophysiological profile of the mouse heart shows major differences compared to 
human. They have faster heart rates and different repolarizing currents as well [16]. This 
might result some differences in arrhythmia mechanisms [44,45]. According to these 
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discrepancies, there is a need to provide transgenic animals which reflect human heart 
physiology better than small rodents. One of the possible species for this purpose is the rabbit, 
which has shown promising results, especially modelling LQT1 and LQT2 diseases [46–48]. 
The electrophysiological profile of the rabbit heart is more comparable to the human heart. It 
shows slower heart rates, similar repolarizing currents and is a commonly used model for 
cardiovascular pharmacology studies [46,48,49]. However, only two types of transgenic 
rabbits have been created (LQT1 and LQT2) so far [50]. In 2003, a novel missense mutation 
was discovered and characterized in a Chinese family [51]. Due to this mutation, arginine (R) 
was substituted for glycine (G) at position 52 of the minK protein, which is the regulatory 
subunit of the IKs channel [52]. Five of the seven patients showed alterations in ECG, and two 
of them had no symptoms [51]. Co-expression of the G52R-KCNE1 with KCNQ1 reduced 
the IKs current by 50% in Xenopus oocytes and caused a prolongation in the cardiac action 
potential [51]. The G52R has no effect on the channel-subunit assembly, or trafficking to the 
cell membrane, but it affects the gating mechanisms of KCNQ1 in CHO-K1 cells [53]. 
4.5 Aims of the study 
 
The aim of this study was to validate two models as possible tools for cardiac safety 
pharmacology and disease modelling: 
 
1) Compare the IK1 current density in hiPSC-CM under two different culture 
conditions (ML and EHT) and compare them to CM isolated from human right 
atrial and left ventricular tissue.  
 
2) Investigate whether hiPSC-CM exhibit a ventricular or atrial phenotype based on 
channel expression (possible expression and function of acetylcholine-sensitive 
K
+
 current (IK,Ach) and specific action potential parameters (repolarization 
fraction).  
 
3) Study resting membrane potential in hiPSC-CM EHTs using two different 
approaches (patch clamp and sharp microelectrode technique). 
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4) Create and characterise a novel LQT5-TG rabbit model with impaired 
repolarization reserve and study the cellular electrophysiological profile (in case 
of potassium currents) of the animals using the patch clamp technique. 
 
5) Evaluate the in vivo electrophysiological parameters of the LQT5-TG rabbit 
model and its reaction to dofetilide-induced arrhythmia provocation. 
 
5 Methods 
 
5.1 Human samples 
 
Myocardial tissue was obtained from patients undergoing cardiac surgery at the 
University Heart Centre Hamburg. The study followed the Declaration of Helsinki. All 
patients gave written informed consent. Human right atrial appendages were obtained from 
patients undergoing cardiac surgery. They were immediately placed into cold Ca
2+
-free 
transport solution (in mmol/L: NaCl 100, KCl 10, KH2PO4 1.2, MgSO4 5, taurine 50, MOPS 
5, and glucose 20, with pH adjusted to 7.0 with NaOH) supplemented with 2,3-butanedione 
monoxime (BDM, 30 mmol/L). Before the isolation, the tissue was cut into small pieces, and 
washed 3 times for 3 minutes with Ca
2+
-free Tyrode‟s solution. During the procedures, the 
solutions were oxygenated with 100% O2 at 35 °C. Tissue pieces were then transferred into 
Ca
2+
-free Tyrode‟s solution containing 254 U/mL collagenase type I (Worthington 
Biochemical Corp. Lakewood, NJ, USA) and 0.5 mg/mL protease type XXIV (Sigma 
Chemical Co) and gently stirred for additional 15 minutes. Then the Ca
2+
 concentration was 
raised to 0.2 mmol/L, and the tissue was stirred for 30 minutes more.  
5.2 Differentiation of hiPSC-CM and EHT generation 
 
The undifferentiated hiPSC line C25 (kind gift from Alessandra Moretti, Munich, 
Germany) was expanded in FTDA medium [54] and differentiated in a three step protocol 
based on growth factors and a small molecule Wnt-inhibitor DS07 (kind gift from Dennis 
Schade, Dortmund, Germany) as previously published [40,55]. In brief, confluent 
undifferentiated cells were dissociated (0.5 mM EDTA; 10 min) and cultivated in spinner 
flasks (30*106 cells/100 ml; 40 rpm) for embryoid body formation overnight [56]. 
Mesodermal differentiation was initiated in embryoid bodies over three days in suspension 
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culture with growth factors (BMP-4 [R&D Systems, 314-BP], activin-A [R&D Systems, 338-
AC], FGF2 [PeproTech, 100-18B]). Cardiac differentiation was performed either in adhesion 
or in suspension culture with Wnt-inhibitor DS07 [55]. Cells were cultured in a humidified 
temperature and gas-controlled incubator (37 °C, 5% CO2, 5% O2; 21% O2 for final cardiac 
differentiation). At day 14 the spontaneously beating hiPSC-CM were dissociated with 
collagenase type II (Worthington, LS004176; 200 U/ml, 3.5 h) and either cultured in ML or 
EHT format. For three-dimensional culture EHT were generated as previously described with 
1x106 cells / 100 µl EHT [57]. EHT as well as ML were cultured in a 37 °C, 7% CO2, 40% 
O2 humidified cell culture incubator with a medium consisting of DMEM (Biochrom; F0415), 
10% heat-inactivated horse serum (Gibco 26050), 1% penicillin/streptomycin (Gibco 15140), 
insulin (10 µg/ml; Sigma I9278) and aprotinin (33 µg/ml; Sigma A1153). For further 
comparability, experiments were performed in parallel from the same batch of cells. 
5.3 Dissociation of hiPSC-CM from ML and EHT 
 
HiPSC-CM were cultivated for 28 days in ML or EHT culture before dissociation. The 
cells were isolated for 3 h (ML) and 5 h (EHT) using collagenase type II (200 U/ml, 
Worthington Biochemical Corp. Lakewood, NJ, USA, LS004176 in HBSS minus Ca
2+
/Mg
2+
, 
Gibco 14175-053 and 50 µM CaCl2). At least 3 different batches of hiPSC-CM were used for 
each culture conditions. During dissociation, we performed a small mechanical friction after 
1.5 h and 3 h. After the enzymatic digestion, we plated the cardiomyocytes on gelatine-coated 
(0.1%) glass coverslips (12 mm diameter, Carl Roth GmbH+Co, Karlsruhe, Germany). The 
cells were used in maximum 48 hours after the plating for patch clamp experiments, to avoid 
changes in morphology and ion currents due to culture conditions as much as possible. 
5.4 Inward rectifier potassium current recordings in hiPSC-CM 
 
Inward rectifiers were measured at room temperature (RT), using the whole-cell 
configuration of the patch clamp technique. Axopatch 200B amplifier (Axon Instruments, 
Foster City, CA, USA) and ISO2 software were used for data acquisition and analysis (MFK, 
Niedernhausen, Germany). Heat-polished pipettes were pulled from borosilicate filamented 
glass (Hilgenberg, Malsfeld, Germany). Tip resistances were 2.5–5 MΩ, seal resistances were 
2–4 GΩ. The cell-containing coverslips were settled into a small perfusion chamber, placed 
on the stage of an inverse microscope. An agarose bridge was placed into a solution 
containing high KCL to minimize the liquid junction potential. During the measurements, the 
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following external solution was used (in mM): NaCl 120, KCl 20, HEPES 10, CaCl2 2, MgCl2 
1 and glucose 10 (pH 7.4, adjusted with NaOH). Contaminating Ca
2+
 currents were inhibited 
with the selective L-type calcium channel blocker nifedipine (10 µM). The internal solution 
for measuring IK1 and IK,ACh included the following (in mM): DL-Aspartate potassium salt 80, 
KCl 40, NaCl 8, HEPES 10, Mg-ATP 5, Tris-GTP 0.1, EGTA 5 and CaCl2 2, pH 7.4, 
adjusted with KOH. Inward current amplitudes were determined as currents at –100 mV. A 
single concentration (2 µM) of the muscarinic receptor agonist carbachol (CCh) was used to 
evoke IK,ACh. 
5.5 Current clamp recordings in hiPSC-CM 
 
Action potentials were recorded using the perforated patch (Amphotericin B) 
configuration of the patch clamp technique. We switched the Axopatch 200B (Axon 
Instruments, Foster City, CA, USA) to current clamp mode. The experiments were performed 
at 37 °C, 1 Hz, using the following external solution (in mM): NaCl 120, KCl 5.4, HEPES 10, 
CaCl2 2, MgCl2 1 and glucose 10 (pH 7.4, adjusted with NaOH). The internal solution was (in 
mM): DL-aspartate potassium salt 80, KCl 40, NaCl 8, HEPES 10, Mg-ATP 5, Tris-GTP 0.1, 
EGTA 5 and CaCl2 2 (pH 7.4, adjusted with KOH,). For both voltage and current clamp 
recordings, the liquid junction potential was calculated to –12 mV, using the JPCalcW 
software (SDR Scientific, Sydney, Australia). To reach the perforated patch configuration the 
tip of the pipettes were filled with the internal solution complemented with 20 µg/ml 
Amphotericin B. The perforated patch configuration was reached in a few minutes after 
gigaseal formation. In action potential recordings the repolarization fraction was calculated by 
the following way: (APD50–APD90)/APD90 [58]. 
5.6 Sharp microelectrode recordings in hiPSC-CM 
 
We used the sharp microelectrode technique to record action potentials from right atrial 
and left ventricular trabeculae and from intact EHT. The tip resistance of the microelectrodes 
were between 20 and 50 MΩ (when filled with 3 mM KCl). Action potentials were elicited by 
field stimulation at 1 Hz: 0.5 ms stimulus, 50% above threshold intensity. The following bath 
solution was used (in mM): NaCl 125, KCl 5.4, MgCl2 0.6, CaCl2 1, NaH2PO4 0.4, NaH2CO3 
22, and glucose 5.5 and was equilibrated with O2–CO2 (95:5). The experiments were 
performed at 37 °C. 
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5.7  Quantification of transcript levels 
 
The RNeasy® Plus Mini Kit (Qiagen, Venlo, The Netherlands) was used to isolate total 
RNA from human heart tissue, cardiomyocytes cultured in ML and dissociated EHT. For 
quantification of transcript levels, cDNA was generated using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Quantitative PCR was performed with the 
5x HOT FIREPol® EvaGreen® qPCR Mix Plus (ROX) (Solis BioDyne, Tartu, Estonia) on 
ABI PRISM 7900HT Sequence detection system (Applied Biosystems, Foster City, 
California, USA). Relative transcript levels were calculated using the ΔCT-method with 
glucuronidase beta (Gusb) as a housekeeping gene. 
5.8 Animals and ethical considerations 
 
New Zealand White rabbits were obtained from Tetrabbit Kft. (Hungary). The animals, 
which were used during the experiments, were young adults (approximately 3.5 kg) of either 
sex, unless otherwise indicated. The animals were kept in stainless steel rabbit cages 
containing an elevated resting place. These parameters are fulfilling the requirements of 
authorities in terms of size and environmental enrichment. Rabbits were individually housed 
and were kept at standard temperature, humidity and lighting. Food and water were provided 
ad libitum. The water was provided in separate drinking bowls allowing each animal to access 
it. The water was regularly checked for quality and any pathogens. Collection of zygotes and 
laparoscopic transfer of injected embryos to recipient rabbits was performed as described 
earlier [59]. Pseudo pregnant animals were moved to a nesting cage 3–4 days before expected 
delivery date. The rabbits were anaesthetized with ketamine-S/xylazine i.m. (12.5 and 3.5 
mg/kg
-1
) or thiopental (50 mg/kg
-1
) through marginal ear vein during in vivo ECG studies. At 
the end of the arrhythmia provocation experiments, the anaesthetized animals were sacrificed 
by i.v. administration of pentobarbital sodium (RELEASE) in a dose of 300 mg/mL. All 
animal care and experimental protocols complied with the Guide for the Care and Use of 
Laboratory Animals (USA NIH publication NO85–23, revised 1996) and conformed to the 
Directive 2010/63/EU of the European Parliament; they were approved by the Animal Care 
and Ethics Committee of the Agricultural Biotechnology Centre and the Ethical Committee 
for the Protection of Animals in Research of the University of Szeged (approval number: I-
74-5-2012) and by the Department of Animal Health and Food Control of the Ministry of 
Agriculture and Rural Development (authority approval numbers 22.1/433/003/2010 and 
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XIII/1211/2012). Animal studies are reported in compliance with the ARRIVE guidelines 
[60] and the editorial on reporting animal studies [61]. 
5.9 Creation of LQT5-TG rabbits 
 
The KCNE1 coding region of the transgene was amplified and analysed by automated 
sequencing. The MYH7- G52R-KCNE1-bGHpolyA insert was isolated and used to 
microinject rabbit embryos [62]. Out of 497 injected embryos, 466 were transferred into 21 
pseudo pregnant recipients through laparoscopy. Thirty-eight offspring (8%) were born alive, 
out of which four (10%) were transgenic by genomic PCR. Three founders lived till sexual 
maturity. The female founder did not transmit the transgene to its offspring, suggesting that it 
was transgenic in somatic tissues but not the germ line. The remaining two transgenic founder 
males (# G52R-JTJKK and #G52R-JKK) transmitted the transgene to their offspring from 
wild-type (WT) does at 52% (in the G52R-JTJKK line) and 15% (in the G52R-JKK line) 
ratio, respectively, which in case of the G52R-JTJKK founder underlines a Mendelian type 
inheritance. For the #G52R- JKK founder, the transgene transmission data indicate a high 
degree of germ-line mosaicism. Therefore, except where it is otherwise indicated, for 
electrophysiological examinations, the F1 hemizygote offsprings of #G52R-JTJKK line were 
used and are called transgenic animals in the figures. The presence of G52R mutation was 
checked by sequencing the PCR product isolated from genomic DNA of the founder male 
#G52R-JTJKK. In the #G52R-JTJKK animal, the transgene was integrated at Σ 10 copies in 
two different loci on Chr11, namely at positions chr11:18,313,856 and chr11:41,935,523.  
5.10 Isolation of rabbit ventricular myocytes 
 
Single ventricular myocytes were isolated enzymatically from the left ventricle of WT 
and LQT5-TG rabbit hearts. Following heparin administration (400 NE/kg
-1
, i.v.), sedation 
with xylazine (1 mg/kg
-1, 
i.v.) and thiopental (30 mg/kg
-1
, i.v.) induced anaesthesia, each heart 
was rapidly removed through a right lateral thoracotomy and placed into cold (4–8 °C) 
solution which contained (in mM): NaCl 135, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, HEPES 10, 
NaHCO3 4.4, glucose 10, taurine 20, CaCl2 1, (pH 7.2). The heart was then mounted on a 
modified, 60 cm high Langendorff column and perfused with oxygenated perfusate of the 
same composition warmed to 37 °C. After 3–5 min of perfusion to flush blood from the 
coronary vasculature, the perfusate was switched to one having no exogenously added 
calcium (i.e. to one that was nominally Ca
2+
-free) until the heart ceased to contract (~8–10 
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min). For Enzymatic digestion the heart was perfused with a Ca
2+
-free solution containing 
290 U/mL
-1
 collagenase type II (Worthington, Biochemical Corp. Lakewood, NJ, USA) and 
30 μM CaCl2. After 10-15 min perfusion, the heart was removed from the aortic cannula and 
placed into enzyme-free solution containing 1 mM CaCl2 warmed to 37 °C for 10 min. After 
that the tissue was chopped into small pieces, and following a gentle agitation, myocytes were 
separated by filtering the resulting slurry through a nylon mesh. Myocytes were finally 
harvested by gravity sedimentation. Once the majority of individual myocytes settled to the 
bottom of the container, the supernatant was decanted and replaced with Tyrode‟s solution, 
and the myocytes were re-suspended by gentle agitation. This procedure was repeated twice 
more, and the resulting myocyte suspension was stored in HEPES-buffered Tyrode‟s solution 
at RT. 
5.11 Voltage-clamp measurements on rabbit ventricular cardiomyocytes 
 
The freshly isolated cardiomyocytes were placed into a transparent recording chamber 
mounted on the stage of an inverted microscope (Olympus IX51, Tokyo, Japan). The cells 
were superfused with a perfusion system maintained by gravity.  Only rod-shaped cells with 
clear striations were used. For the recordings a HEPES-buffered Tyrode‟s solution 
(composition in mM: NaCl 144, NaH2PO4 0.4, KCl 4.0, CaCl2 1.8, MgSO4 0.53, glucose 5.5 
and HEPES 5.0, at pH of 7.4) was used as an external solution. Micropipettes were pulled 
from borosilicate glass capillaries (Science Products GmbH, Hofheim, Germany), using a P-
97 Flaming/Brown micropipette puller (Sutter Co, Novato, CA, USA), with a tip resistance of 
1.5-2.5 MΩ. The glass electrodes were filled with the following internal solution (in mM): 
KOH 110, KCl 40, K2ATP 5, MgCl2 5, EGTA 5, GTP 0.1 and HEPES 10, pH was adjusted to 
7.2 by aspartic acid. Transmembrane ion currents were recorded using the whole cell 
configuration of the patch clamp technique. Axopatch-200B amplifiers (Molecular Devices, 
Sunnyvale, CA, USA) were used for the recordings and the membrane currents were digitized 
with 250 kHz analogue to digital converters (Digidata 1440A, Molecular Devices, Sunnyvale, 
CA, USA) under software control (pClamp 8 and pClamp 10, Molecular Devices, Sunnyvale, 
CA, USA).  
The inward rectifier (IK1), transient outward (Ito), rapid (IKr) and slow (IKs) delayed-
rectifier potassium currents were studied in rabbit ventricular myocytes. Nisoldipine (1μM), 
was used to block ICa,L. During IKr measurements, IKs was inhibited by the selective blocker 
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HMR 1556 (0.5 μM). Dofetilide (0.5 μM) was used to block IKr, when IKs was investigated.. 
The external solution contained 0.1 μM forskolin. All experiments were performed at 37°C. 
5.12 ECG recording and evaluation 
 
 Rabbits were anaesthetized either with ketamine-S/xylazine i.m. (12.5 and 3.5 mg·kg-1) 
or thiopental (50 mg·kg-1) with injection through the marginal ear-vein. A catheter was 
inserted into the carotid artery for blood-pressure measurement. The right jugular vein was 
cannulated for i.v. drug administration. Blood pressures and electrocardiograms were 
continuously recorded, digitized and stored for off-line analysis. RR and QT intervals were 
measured as the average of 30 beats. For QT-interval measurements, published guidelines 
were followed [63]. The frequency-corrected QT interval (QTc) was calculated by a specific 
formula for thiopental-anaesthetized rabbits [64]: QTc=QT–[0.704*(RR-250)]. In 
ketamine/xylazine anaesthetized animals, heart rate-corrected QT-indices were calculated as: 
QTi (%)=QTmeasured*100/QTexpected; QTexpected=86+0.22 * RR) as described previously [50]. 
I.v. infusions were administered with a programmable infusion pump (Terufusion TE-3, 
Terumo Europe, Leuven, Belgium). Both WT and LQT5-TG rabbits received dofetilide (20 
μg/kg-1) over 10 min.  
5.13 Short-term variability of RR and QT intervals 
 
The short-term beat-to-beat variability of the QT interval was calculated to predict 
arrhythmia-propensity in animal models [65,66] and patients [67,68] reliably. Poincaré plots 
were constructed by plotting all RR and QT values against their preceding values (Figure 17) 
to characterize the temporal instability of beat-to-beat heart rate and repolarization. In case of 
TdP arrhythmia, the measurements were taken prior to TdP. Beat-to-beat short-term 
variability (STV) of RR or QT intervals was calculated as: STV = ∑ |Dn+1-Dn|(30x√2)
-1
,with 
D the duration of QT or RR interval. STV represents the mean orthogonal distance to the line 
of identity on the Poincaré plot; the estimation of beat-to-beat instability of RR and QT 
intervals is as described previously [69]. 
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5.14 Statistical analysis 
 
Data are shown as means ± SEM. For graphical and statistical data analysis the ORIGIN 
8.1 (Microcal Software, Northampton, MA, USA) and the GraphPad Prism Software 5.02 
(GraphPad Software, San Diego, CA, USA) were used. Statistical differences were evaluated 
by using the Student‟s t-test (paired or unpaired) or repeated measures ANOVA, followed by 
Bonferroni test, where appropriate. Linear correlations, concentration-response curves were 
fitted to mean data points and –logIC50 values were compared by F-test using the GraphPad 
Prism Software 5.02. R software (ver. 3.3.1, R Core Team, 2013) was used for the analysis of 
frequency distribution. Please note that the statistical term “Kernel density estimation” is used 
in Figure 12, with, a “kernel” defined as a probability density function which must possess the 
following properties: even non-negative, real-valued and its definite integral over its support 
set must equal to 1. Therefore, “kernel density estimation” is a non-parametric method, which 
allows estimating the probability density function of a random variable (http://scikit-learn.org/ 
stable/modules/density.html). Differences were considered significant when P < 0.05.  
5.15  Drugs and chemicals 
 
All drugs and chemicals were obtained from Sigma-Aldrich (St. Louis, Missouri, USA), 
except for dofetilide (Sequoia Research Products Ltd., Pangbourne, UK and Gedeon Richter 
Ltd., Budapest, Hungary) and nisoldipine (gift from Bayer AG, Leverkusen, Germany). 
 
6 Results 
 
Inward rectifiers and RMP in hiPSC cardiomyocytes 
 
6.1 hiPSC-CM can possess large inward rectifier potassium currents 
 
 Inward rectifiers were measured with a classical ramp protocol (Figure 5B, inset). To 
activate larger inward currents, we applied 20 mM extracellular potassium (Figure 5A, B) 
[70]. It has been reported that applying higher external K
+ 
concentration can reduce leakage 
and improve the stability of the measurements [71]. In every CM (LV and RA) and hiPSC-
CM from both ML and EHT, inward rectifiers could be observed (Figure 5C). High 
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concentration of Ba
2+
 blocked the inward rectifier current in every CM (ML, EHT, RA and 
LV). 
 
Figure 5. Cell size and inward rectifier potassium current (IK1) in hiPSC-CM from ML, EHT, RA and LV. 
A, B: Original traces of and time courses of IK1 currents at –100 mV in hiPSC-CM obtained from ML and EHT 
exposed to 1 mM Ba
2+
. Voltage protocol is given as inset in B. C: Ba
2+
-sensitive IK1 current amplitudes 
measured at –100 mV plotted against cell capacitance; dotted lines indicate linear regression fit (R2 values were: 
0.1 for ML, 0.28 for EHT, 0.15 for RA and 0.007 for LV. D: Individual data points and respective mean 
values±SEM for Ba2+-sensitive IK1 current densities measured at –100 mV in hiPSC-CM from ML, EHT and in 
CM from RA, and LV *P<0.05, **P<0.01, ***P<0.001 (One-way ANOVA followed by Bonferroni test). 
n/n=number of experiments/number of isolations in hiPSC-CM and number of experiments/number of patients 
in RA and LV. 
Inward current amplitudes were plotted vs. cell capacitance to test if larger cells show 
more mature phenotype with higher IK1 (Figure 5C). As shown before [36,72], hiPSC-CM, 
isolated from ML or EHT, were smaller than CM from RA or LV (30.8±1.5 pF, n=167 in ML, 
47.0±1.7 pF, n=260 in EHT, 73.6±4.0 pF, n=55 in RA, 88.8±13.2 pF, n=15 in LV). Only a 
weak positive association could be seen between current amplitude and cell membrane 
capacitance (Cm). The steepness of the regression lines was low in all groups and did not 
differ between hiPSC-CM and human adult CM (Figure 5C, p=0.6, one-way ANOVA). 
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Statistical significance for slope different from zero was reached only in ML, EHT and RA 
(R
2
 values were 0.09 for ML, 0.28 for EHT and 0.14 for RA). This argues against the 
assumption that smaller hiPSC-CM represent a more immature phenotype with smaller IK1 
current amplitude. To have a direct comparison with previous reports, we normalized current 
amplitudes to cell size. The density of the current in ML did not differ significantly from LV 
(Figure 5D). IK1 density in EHT was smaller than in ML and LV, but was comparable to the 
density found in RA (Figure 5D). Thus, IK1 current densities in hiPSC-CM were not lower 
than in human adult CM, when the same experimental conditions were used. 
6.2 IK1 in hiPSC-CM is conducted via highly Ba
2+
-sensitive Kir channels 
 
 
The channel conducting IK1 exists as a tetramer assembled from different α-subunits 
(Kir2.1-2.4) [39]. There is a difference in Ba
2+
-sensitivity of the channel forming subunits of 
IK1  [73,74]. Cardiac myocytes express Kir2.1, 2.2 and 2.3, which are highly sensitive to Ba
2+
 
(in the low µM range) [74]. Kir2.4 exhibits lower Ba2+-sensitivity, and it is expressed in 
neuronal tissue only [73]. To test if IK1 in hiPSC-CM is conducted by the cardiac subunits, 
concentration-response curves were measured for Ba
2+
-block on the inward IK1 current (Figure 
7A). The concentration-response curve was monophasic, arguing against the contribution of 
Kir2.4 in hiPSC-CM (Figure 7B). IK1 in hiPSC-CM from both culture conditions showed 
higher Ba
2+
-sensitivity than in RA: the logIC50 values for Ba
2+
 were –6.09 (95 % confidence 
interval (CI: –6.27 to –5.91) in ML, vs. –6.15 (CI: –6.32 to –5.99) in EHT, vs. –5.66 in RA 
(CI –5.92 to –5.41, p<0.01, F-test for ML vs. RA and for EHT vs. RA, Figure 7B). We found 
the same during RT-qPCR measurements, which confirms that the cardiac isoforms of the Kir 
channels (2.1-2.3) are expressed in hiPSC-CM (Figure 6A, B and C), while Kir2.4 is not 
(Figure 6D). 
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Figure 6. Expression of IK1 channel forming subunits in hiPSC-CM and human adult CM. 
A, B, C, and D: Transcript levels of IK1 channel-forming subunits Kir 2.1, 2.2, 2.3 and Kir2.4 were normalized 
to housekeeping gene (GUSB). *P<0.05, **P<0.01, ***P<0.001 (One-way ANOVA followed by Bonferroni 
test). n/n=number of experiment/number of isolations in hiPSC-CM and number of experiment/number of 
patients in RA and LV.  
 
6.3 The outward IK1 is small in hiPSC-CM 
 
In cardiac myocytes, the outward component of IK1 (the K
+
-conductance in outward 
direction) contributes to the final phase of the repolarization [75]. Therefore, maximum 
outward current density of IK1 was measured during ramp pulses (Figure 7C). In line with the 
previous findings, in human CM, the outward IK1 current density was lower than the inward 
branch and smaller in human atrial than in ventricular CM (0.7±0.25 pA/pF vs. 1.7±0.6 
pA/pF, n=16 and 13, Figure 7D). 
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 Figure 7. Ba2+-sensitivity and outward component of IK1 in hiPSC-CM and human adult CM. 
A: Time course of inward currents measured at –100 mV in a hiPSC-CM from ML exposed to increasing 
concentrations of Ba
2+
. B: Concentration-response curves for Ba
2+
 on inward current at –100mV in hiPSC-CM 
from ML, EHT and in CM from RA. Mean values±SEM. C: Ba2+-sensitive current trace from hiPSC-CM from 
ML. Outward component of current given on an extended scale on top. D: Mean values±SEM of maximum 
outward peak currents in hiPSC-CM from ML, EHT and in CM from RA and LV. n/n=number of 
experiment/number of isolations in hiPSC-CM and number of experiment/number of patients in RA and LV.  
The outward component of IK1 in hiPSC-CM was as small as in RA (1.1±0.2 pA/pF, 
n=67 in ML, 0.8±0.2 pA/pF, n=56 in EHT, Figure 7D). Thus, hiPSC-CM from both ML and 
EHT showed small outward contribution of IK1 as known for human adult CM. The finding 
that hiPSC-CM have small outward IK1 suggests stronger APD prolongation upon block of IKr 
[75]. Therefore, prediction of QT-prolongation in human by hERG-blockers could be more 
meaningful, when hiPSC-CM are used instead of canine or rabbit. Further studies are needed 
to investigate whether hiPSC-CM quantitatively reflect the repolarization reserve in human 
heart. 
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6.4 Acetylcholine-activated potassium currents (IK,ACh) are not expressed in hiPSC-
CM  
 
Figure 8. Lack of carbachol effect on inward rectifier in hiPSC-CM. 
A: Original traces of inward rectifier currents and time courses of current at –100 mV in hiPSC-CM obtained 
from ML exposed to carbachol (CCh, 2µM). B: CCh effect expressed as absolute current change in response to 
CCh (2 µM) in ML, EHT and in CM from RA. Individual data points and mean values±SEM. C: Transcript 
levels of IK.ACh channel-forming subunits Kir 3.1 and Kir 3.4 in ML, EHT, RA and LV *P<0.05, **P<0.01, 
***P<0.001 (One-way ANOVA followed by Bonferroni test). n/n=number of experiment/number of isolations 
in hiPSC-CM and number of experiment/number of patients in RA and LV. 
 
IK,ACh current is typically expressed in atrial tissue [76]. To activate IK,ACh, the 
muscarinic (M2) receptor agonist carbachol (CCh, 2 µM) was applied during the 
measurements (Figure 8A and B). In RA-CM, CCh activated a large inward current (Figure 
8C and D), which was not present in hiPSC-CM (ML and EHT, Figure 8A, B and D). On the 
expression level, large expression of Kir3.1 was found in RA, but not in LV, ML or EHT 
(Figure 9A). Interestingly, Kir3.4 was expressed in hiPSC-CM under both culture conditions 
at least as high as in RA (Figure 9B).This finding suggests that expression of Kir3.4 in hiPSC-
CM alone cannot generate IK,ACh [39]. The lack of IK,ACh indicates that hiPSC-CM did not 
exhibit an atrial phenotype. 
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Figure 9. Expression of IK,ACh channel forming subunits in hiPSC-CM and human adult CM. 
A, B: Transcript levels of IK.ACh channel-forming subunits Kir 3.1 and Kir 3.4 were normalized to housekeeping 
gene (Gusb). *P<0.05, **P<0.01, ***P<0.001 (One-way ANOVA followed by Bonferroni test). n/n=number of 
experiment/number of isolations in hiPSC-CM and number of experiment/number of patients in RA and LV. 
 
6.5 RMP and AP measurements in single cells and intact tissues 
 
 
To decide whether the relatively normal IK1 densities observed in hiPSC-CM result in 
physiological RMP, action potentials were measured in isolated CM by patch clamp technique 
(Figure 10, left column titled “Patch”). The RMP was low in hiPSC-CM when patch clamp 
electrodes were applied (–39.3±6.1 mV, n=12). To record a stable AP, holding current needed 
to be injected in most of the hiPSC-CM (40 out of 41 in EHT). The amount of holding current 
was in the range of 0.2 nA. After that we were able to record AP with a relatively low RMP in 
EHT (–59.7±1.2 mV, n=41). In contrast, AP could be recorded in human adult CM from RA 
and LV without application of holding current, and in both, RMP were significantly more 
negative than in EHT. Respective RMP amounted to –74.4±0.5 mV in RA (n=49) and to –
75.9±1.1 mV in LV (n=10, Figure 12B upper panel). To decide if the measured low RMP 
with lower IK1 amplitude is related to methodological issues in hiPSC-CM, we used the sharp 
microelectrode technique on EHT, and we compared them to a larger number of recordings 
measured in intact right atrial and left ventricular preparations (Figure 10 column titled 
“Sharp”, Figure 11C, D). 
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Figure 10. Original AP-recordings taken from EHT, RA and LV. Action potential recorded by patch clamp 
(left) and sharp microelectrode (right) technique. The patch clamp recordings were measured from isolated CM, 
while the sharp microelectrode recordings were measured from intact muscle preparations. In case of isolated 
hiPSC-CM from EHT, the recording was made after injection of holding current. 
 
The EHTs were beating spontaneously, slightly slower than 60 bpm, which allowed us 
to record stimulated AP at 1 Hz. RMP in sharp microelectrode recordings was significantly 
less negative in RA than in LV (–73.3±0.3 mV, n=220 vs. –75.9±0.7 mV, n=57; p<0.001, 
Figure 12B lower panel). RMP in intact EHT (–74.6±1.2 mV, n=24) was similar to RA and 
LV (Figure 12B lower panel). At this point, it should be emphasized that IK1 density alone 
does not determine RMP, but the relation of all conductance present near RMP [75]. Two 
other parameters, APD90 and repolarization fraction - calculated as (APD90-APD50)/APD90 - 
are commonly used as a tool to distinguish between atrial-like and ventricular-like hiPSC-CM 
[58]. 
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Figure 11. Individual distribution of APD90, RMP and repolarization fraction in EHT, RA and LV.  
A, C: Individual data points of APD90 plotted vs. respective RMP values measured by patch clamping of isolated 
CM from EHT, RA and LV and by sharp microelectrodes in intact tissues from EHT, RA and LV. B, D: 
Individual data points of repolarization fraction vs. APD90 in isolated CM: from EHT, RA and LV and in intact 
tissues: EHT, RA and LV (One-way ANOVA followed by Bonferroni test). 
It should be noted that impact of IK1 on APD90 in human LV is very small, and 
repolarization fraction is mainly dominated by the activity of transient potassium outward 
currents. Both parameters are probably rather independent of IK1 [75]. Nevertheless, we aimed 
to determine if adult human cardiac tissue from RA and LV can be classified correctly and, 
more importantly, whether hiPSC-CM represent atrial-like or ventricular-like phenotype or a 
mixture of both. Using patch clamp electrodes, APD90 was shorter in RA than in LV (220±16 
ms, n=41 vs. 434±39 ms, n=10; p<0.001, and even shorter in hiPSC-CM (119±17 ms, n=41, 
p<0.001 vs. RA p<0.01 vs. LV, Figure 12A upper panel).  
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Figure 12. Frequency distribution of APD90, 
RMP and repolarization fraction in EHT, RA 
and LV. 
A, B, and C: Frequency distribution expressed 
as kernel density and mean values for APD90, 
RMP and repolarization fraction. Data obtained 
by patch clamping of isolated CM from EHT, 
RA and LV are given in the upper panels,  
measured by sharp microelectrodes in intact 
tissues from EHT, RA and LV are given in the 
lower panels.  *P<0.05, **P<0.01, ***P<0.001 
(One-way ANOVA followed by Bonferroni test). 
 
 
We could observe a substantial overlap in APD90, if we took individual data points of 
RA and LV from patch clamp experiments (Figure 11A, B, Figure 12A upper panel). When 
sharp microelectrode technique was used, APD90 scatter was lower than in patch clamp 
recordings (Figure 11C). The mean APD90 was shorter in RA than in LV (317±3 ms, n=220 
vs. 334±6 ms, n=57; p<0.05 Figure 12A bottom panel). Again, APD90 was clearly shorter in 
EHT 271±11.4 ms, n=24; p<0.001 vs. RA and p<0.001 vs. LV, Figure 12A bottom panel). 
Next, it was retrospectively evaluated whether differences in repolarization fraction would be 
a useful parameter to differentiate between LV and RA. We could only observe a narrow 
distribution of repolarization fraction in AP measurements from intact muscle preparations 
(Figure 12C, bottom panel). The overlap between LV and RA was really small, which 
indicates that repolarization fraction can be a useful approach to distinguish between atrial 
and ventricular phenotype (Figure 11D). Repolarization fraction of intact EHT was similar to 
LV and differed significantly from RA (EHT: 0.32±0.01 n=24 vs. RA: 0.54±0.01 n=220 vs. 
LV 0.28±0.01 n=57, Figure 12C bottom panel). In contrast to sharp microelectrode 
recordings, measurements of repolarization fraction in individual CM showed a wide range of 
distribution (Figure 11B, Figure 12C, upper panel). 
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In vitro and in vivo electrophysiological characterization of a novel LQT5-TG rabbit model 
6.6 Potassium currents in healthy and LQT5-TG rabbit ventricular myocytes 
 
In myocytes, isolated from LQT5-TG, which carries the mutant minK (G52R) subunit 
of IKs, the density of the transient outward potassium current (Ito) was moderately, but 
significantly larger than in WT rabbits (Figure 13A). There was no difference in inward-
rectifier potassium current (IK1) density between the two groups (Figure 13B). The amplitude 
(Figure 14A) and the inactivation time (Figure 14B) constant of the IKr tail current were not 
different between the WT and LQT5-TG myocytes. The fast deactivation time constant of IKr 
(at −40 mV, test potential: 30 mV) was slightly faster in LQT5-TG rabbit cells compared with 
WT (Figure 14B).  
 
Figure 13. The density of I
to
 and I
K1
 in rabbit ventricular myocytes.  
A: Representative I
to
 current traces recorded from WT and LQT5-TG ventricular myocytes are shown left. 
Current–voltage relations (right) demonstrate higher I
to
 density in LQT5-TG rabbits compared with WT rabbits. 
B: Steady-state current–voltage curves (left) demonstrating no differences in density of I
K1
 between WT and 
LQT5-TG rabbits. The outward current sections of the curves are enlarged on the right. Insets show the applied 
voltage protocols. Values are means ± SEM. 
*
P < 0.05 versus WT littermates. 
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No difference was observed in IKs tail-current amplitude between LQT5-TG and WT 
rabbits (Figure 15A). The stimulating effect of forskolin on IKs was similar in WT versus 
LQT5-TG rabbits (Figure 15A). There were no difference in the activation kinetics of IKs, 
however the deactivation kinetics was (at −40 mV, test potential: 50 mV) was markedly and 
significantly faster, in LQT5-TG rabbit myocytes compared with WT rabbits (Figure 15B). 
These changes would be expected to reduce phase-3 repolarizing current, especially if the 
repolarization reserve is reduced. The subtle repolarization abnormalities associated with our 
model were reflected in cellular action-potential recordings, which showed a significant 
increase in APD-variability, but not in APD-increase resulting from dofetilide exposure in 
LQT5-TG vs. WT rabbits. 
 
Figure 14. I
Kr
 in rabbit ventricular myocytes.  
A: Representative I
Kr
 tail current traces recorded from WT and LQT5-TG ventricular myocytes are shown on the 
left. Current–voltage relations (right) demonstrate no differences in density of I
Kr
 between WT and LQT5-TG 
rabbits. Inset shows the applied voltage protocol. B: Bar diagrams illustrating the activation and deactivation 
(fast and slow) time constants in WT and LQT5-TG ventricular myocytes. Values are means ± SEM. 
*
P < 0.05 
versus WT littermates. 
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Figure 15. I
Ks
 in rabbit ventricular myocytes.  
A: Representative I
Ks
 current traces recorded from WT and LQT5-TG ventricular myocytes are shown left. 
Current–voltage relations (right) demonstrate no differences in density of I
Ks
 between WT and LQT5-TG rabbits. 
Inset shows the applied voltage protocol. B: Bar diagrams illustrating the activation and deactivation time 
constants in WT and LQT5-TG ventricular myocytes. Values are means ± SEM. 
*
P < 0.05 versus WT 
littermates. 
 
6.7 ECG parameters and arrhythmias in healthy and LQT5-TG rabbits 
 
During anaesthesia with ketamine/xylazine, which should not affect cardiac 
repolarization [47], there was a slightly, but significantly longer QTi in LQT5-TG versus WT 
littermates (104 ± 0.9% vs. 98.9 ± 1.0%, P < 0.001, Figure 16). No sex-related differences 
were observed. 
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Figure 16. Heart rate corrected QT index in anaesthetized rabbits.  
Plots indicating the heart-rate corrected QT-indices (QTi) in LQT5-TG (n = 21) and WT littermate (n = 22) 
rabbits under anaesthesia with ketamine/xylazine. Mean ± SEM are indicated as horizontal lines. P < 0.001. 
There were no difference in the short-term variability of the RR interval (STVRR) 
between the two groups, both at baseline and following dofetilide injection (Figure 17C). 
Figure 17A and B shows Poincaré plots of QT-intervals of representative individual WT and 
LQT5-TG rabbits. As shown on the representative plots (Figure 17A and B) and on the 
grouped data (Figure 17D), the short-term QT-interval variability (STVQT) was already 
greater in LQT5-TG rabbits at baseline. The QT and QTc intervals were significantly 
prolonged in both groups after dofetilide administration (20 μg/kg−1, i.v.). Interestingly, there 
was a decrease in heart rate in LQT5-TG animals after dofetilide injection. Dofetilide 
significantly increased the STVQT in LQT5-TG animals (Figure 17D). While dofetilide led to 
similar QTc prolongation in both groups, its STVQT-increasing effect was more pronounced 
and accompanied by more arrhythmias in LQT5-TG animals. Dofetilide provoked a greater 
number of TdP arrhythmias in LQT5-TG rabbits (12/15, 80%) than in WT animals (3/11, 
27%, P < 0.001, Figure 17E). The duration of the TdP episodes were also significantly longer 
in LQT5-TG animals, compared to WT rabbits (Figure 17F). 
* 
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Figure 17. Short-term variability of the RR and QT intervals and Torsade-de-Pointes in thiopental 
anaesthetized rabbits.  
A, B: Representative Poincaré plots demonstrate higher short-term beat-to-beat variability of the QT interval 
(STV
QT
) in anaesthetized LQT5-TG rabbits at baseline conditions compared with WT animals. Following the 
administration of the I
Kr
 blocker dofetilide, STV
QT
 further and markedly increased only in LQT5-TG animals. C: 
No differences in short-term variability of the RR interval (STV
RR
) between WT and LQT5-TG rabbits either at 
baseline conditions or following the administration of the I
Kr
 blocker dofetilide. D: Short-term variability of the 
QT interval (STV
QT
) was higher in LQT5-TG animals at baseline conditions and following dofetilide infusion, 
indicating increased temporal instability of repolarization in LQT5-TG rabbits. E: Accordingly, LQT5-TG 
animals exhibited Torsade-de-Pointes (TdP) with significantly higher incidence. F: The duration of TdP 
episodes was significantly longer in LQT5-TG rabbits, expressed as the log
10
 of duration in seconds (to allow 
statistical comparison of data with normal distribution).  Dofetilide (20 μg·kg
−1
, i.v.); n = 11 and 15 animals in 
WT and LQT5-TG groups, respectively on panels C to E; n = 3 and 12 animals on panel (F); 
*
P < 0.05 versus 
WT; 
#
P < 0.05 versus baseline in the same group. 
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7 Discussion 
7.1 Human in vitro models in cardiovascular pharmacology 
 
This thesis summarizes the evaluation of two promising models in cardiovascular 
pharmacology. HiPSC-CM are providing great opportunities not just for studying drug effects 
on human cells, but also to create personalized treatment for patients as well as gene therapy 
and cardiac repair. However, this is restricted to in vitro experiments and several reports 
suggested that the cells show immaturity and differ from adult CM [34,36,37]. In the first 
section of the thesis IK1 density, RMP and AP properties in hiPSC-CM and in human atrial 
and ventricular CM/tissues were directly compared under identical experimental conditions. 
The main findings are that the density of inward IK1 in hiPSC-CM were similar to human CM 
and that sharp microelectrode measurements (of intact 3D heart muscle preparations) provide 
more reliable data on RMP and repolarization fraction than patch clamp recordings (of 
isolated cells). As a side result, repolarization fraction can be a more useful tool than RMP 
and APD in classification of atrial and ventricular cells using sharp microelectrode technique.  
7.2 IK1 in hiPSC-CM and in adult human atrial and ventricular CM 
IK1 density is generally larger in ventricular than in atrial CM [77–80] and very low or 
absent in nodal cells [81,82]. In myocytes, isolated from LV the inward component of the IK1 
was approximately 2.5-fold larger than in RA-CM. In some reports the difference was greater 
[77,79], however one of the first studies and the largest one up to date showed the same 
disparity between RA and LV [78,76]. In contrast to previous publications reporting very low 
to absent IK1 in hiPSC-CM [34,35,37], the density of IK1 in our hiPSC-CM was in the same 
range as in human adult cardiomyocytes.  
IK1 density in hiPSC-CM from ML was not different from human LV-CM. In hiPSC-CM 
dissociated from EHT, the current density was lower than in LV, but still reached the values 
of RA. As culture of hiPSC-CM in EHT leads to signs of advanced maturation, this was an 
unexpected finding, while it was shown before that culturing hiPSC-CM on different 
platforms (for example polydimethylsiloxane) can increase inward IK1 density [35,40]. The 
discrepancy why IK1 was lower in EHT than in ML is not clarified yet.  
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7.3 Measured RMP can differ in hiPSC-CM due to technical issues 
 
 
As shown before in other studies, RMP measured by patch clamp electrodes was much 
lower in isolated hiPSC-CM than in adult human CM [34–38]. However, using sharp 
microelectrodes, the RMP value was in a physiological range in intact EHT. This discrepancy 
raised the question whether RMP measurements with patch clamp electrodes would give a 
systematic error. High seal resistance (in the range of 1-10 GΩ) is critical for the reliability of 
patch clamp recordings especially in cells with lower capacitance. The remaining leak current 
is expected to reduce the actual membrane voltage [78,83]. The corrected membrane potential 
(VcM) can be calculated from the actual seal resistance (Rseal), the membrane resistance (RM) 
and the membrane potential, measured during the experiment (VmM). The equation is the 
following:  
VcM = VmM  + VmM * RM/Rseal , 
if Rseal is considered in series with RM. Rseal in our experiments was between 1 and 10 GΩ, 
both in adult CM and in hiPSC-CM. RM at the RMP is determined by conductivity via IK1. To 
get an estimate of RM generated by IK1, we measured the Ba
2+
-sensitive (1 mM) current under 
the same experimental conditions we used for AP recordings in hiPSC-CM from EHT (5.4 
mM [K
+
]ext 37 °C). As expected, current density of IK1 was smaller and the reversal potential 
was shifted to about –70 mV under these conditions (1.5±0.7 pA/pF, n=12, at 5.4 mM K+[ext] 
vs. 14.1±12.0 pA/pF, n=60 at 20 mM K+[ext], p<0.05). Dividing the actual driving force for 
potassium (~30 mV) by the Ba
2+
-sensitive absolute current amplitude measured at –100 mV 
(41.1±13.7 pA, n=12) gave a membrane resistance of around 0.75 GΩ. If the true RMP is 
assumed to be around –73 mV and a typical seal resistance is about 3 GΩ, according to the 
equation described above, the membrane voltage recorded by patch clamp electrodes will 
drop down to a value of –58 mV. Since we do not have data for IK1 in LV-CM under 
physiological conditions, we used data which was published previously. In Amos et al. (1996) 
the mean IK1 current densities were 1.1 and 2.8 pA/pF in RA and LV [78]. Multiplying the 
values with the capacitances given in that study (145 for RA and 285 pF for LV), we could 
calculate absolute IK1 current amplitudes of ~160 pA in atrial and ~800 pA in ventricular CM 
[78]. If we plot VcM vs. IK1 amplitudes, it reveals that the error in hiPSC-CM will be larger 
compared to human CM due to their small capacitance even at the same seal resistances. If we 
assume the 2.5 times higher IK1 density in ML, it might still not be sufficient to leave the 
larger error zone, since the absolute IK1 current amplitude will reach only 79 pA after 
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calculation. Isolated hiPSC-CM can be fragile, which can cause a dropdown in the seal 
resistance during an experiment. Importantly, the apparent RMP can drastically change due to 
a slight change in seal resistance in cells with low IK1 conductivity. This can be owing to 
combination of low current density and small cell size. It should be noted that these 
calculations are based on mean values for cell size and IK1. Because of the large variability 
both in cell size and IK1 density (Figure 5C), underestimation of RMP may be much larger in 
an individual cell (Figure 18). Therefore, given the present limitations, measurements of AP 
with patch clamp pipettes are prone to error and not well suited as an indirect parameter of IK1 
density. Small cell size is not necessarily an issue, since AP measurements are feasible even 
in much smaller cells, like pancreatic cells, whose size are in the range of 5 pF [84]. Very 
high seal resistance up to 10 GΩ and very large potassium conductance may facilitate AP 
recording in those cells [85].  
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Figure 18. Influence of seal resistance and absolute IK1 amplitude on apparent resting membrane potential 
in patch clamp experiments. 
Curves give calculated apparent RMP as a function of absolute IK1 amplitudes and seal resistance. It is assumed 
that inward current amplitudes are determined by IK1 only. True RMP was assumed to be –73 mV, as indicated 
by the dotted horizontal line. Vertical lines indicate absolute IK1 amplitudes at –100 mV. Dotted vertical lines 
illustrate 95% confidence interval of IK1 measured in EHT. The apparent RMP was calculated by the equation 
VcM = VmM + VmM * RM/Rseal. Please note data for EHT are taken from experiments independent from those 
presented in Figure 5 (numbers given in the section discussion). Data for RA and LV are taken from the 
literature [78]. Numbers near the fit curves indicates seal resistance used for calculation. For details, see 
discussion. 
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7.4 Discrimination of atrial and ventricular cells by IK,ACh, IK1, RMP, APD90 and 
repolarization fraction 
 
In previous studies, it was shown that in standard hiPSC-CM cultures ventricular-, 
nodal and atrial-like myocytes can be found [28,29,36,37,86,87]. In those reports the 
classification is mainly based on differences in AP parameters. In this study the existence 
IK,ACh was used as a different approach. Only atrial and nodal CM express IK,ACh [88,89]. 
There was no response to CCh with a change of inwardly rectifying current in any of the 
hiPSC-CM. The absence of IK,ACh cannot be explained by a lack of muscarinic receptors, since 
CCh reverses positive inotropic effects of isoprenaline in the same hiPSC-EHT [40], the 
classical accentuated antagonism [90]. This finding suggests that hiPSC-CM show at least 
partly ventricular phenotype. As outlined above, different IK1 densities might also 
discriminate between atrial and ventricular CM. However, we found mean IK1 densities to 
differ only moderately between human RA and LV (2.5-fold) and, importantly, to scatter 
largely and substantially overlap between the groups (Figure 5D). Thus, our data do not 
support recent suggestions that IK1 density should be used to discriminate between atrial and 
ventricular phenotype in hiPSC-CM [91].  
RMP is also commonly used for discrimination between atrial and ventricular CM. In 
accordance with the lower IK1 density in atrial cells, mean RMP was more negative in LV than 
in RA. However, although IK1 was 2.5 fold higher in LV than RA, differences in mean RMP 
values were small. Individual RMP measurements broadly overlapped between RA and LV 
both in patch clamp and sharp microelectrode recordings. Thus, the power of RMP to 
discriminate atrial from ventricular CM was modest. If the RMP was more negative than ~ –
82 mV in a tissue, it could be classified as ventricular with an accuracy of 80%, this this 
applied to only approximately 20% of the ventricular preparations. Mean RMP values in EHT 
were similar to RA and LV. RMP in EHT was not significantly different from LV and RA. It 
suggests that RMP is not a useful parameter to decide if EHT possess an atrial or ventricular 
phenotype. In addition, it should be emphasized that IK1 density alone does not determine 
RMP, but the relation of all conductance‟s present, like background sodium and calcium 
currents, NCX and Na
+
/K
+
-ATP-ase [92], many of them not yet studied detailed in hiPSC-
CM. 
AP duration is also often used for classification of hiPSC-CM whether they show atrial- 
or ventricular-like phenotype [34,36–38,86,87]. Such assumptions are based on data from 
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previous publications reporting human APD90 values from various preparations [93–98]. It is 
difficult to use them for direct comparison due to methodological reasons. Here, a greater 
amount of data was provided and the experimental conditions were identical. While mean 
APD90 values were indeed shorter in RA than in LV, individual values again largely 
overlapped. This raises the question again, if individual APD90 values can be a useful tool to 
discriminate between atrial or ventricular phenotype. 
Other approaches were also used for a more precise discrimination between atrial-, and 
ventricular-like APs such as APD90/APD50 [36,99]. The early phase of repolarization in 
human heart is dominated by transient potassium outward currents. In contrast to ventricular 
CM, the transient outward currents in atrial CM exhibit a long lasting component, which 
results in a larger repolarization fraction [78]. In single RA-CM measured by patch clamping 
the repolarization fraction showed a wide range of distribution. This finding is in line with the 
reported wide heterogeneity of transient outward currents in RA-CM [78]. The repolarization 
fraction measured by sharp microelectrode in tissues likely integrates different AP shapes 
from individual cells and therefore the scatter is smaller. This interpretation is supported by 
the observations that mean values did not differ between individual isolated RA-CM and 
intact RA trabeculae. The same holds true for EHT. Due to the smaller distribution of 
repolarization fraction in intact tissues we were able to discriminate clearly between RA and 
LV. Based on this parameter, EHT showed more similarity to LV than RA.  
7.5 Animal models in cardiovascular pharmacology  
 
There is a high need to develop new animal models with a better predictive value for 
proarrhythmic risk. This is important to reflect better the clinical situations at risk of drug 
induced arrhythmias, especially in patient with remodelled myocardium [100] and impaired 
repolarization reserve [101]. In vivo proarrhythmia models with impaired repolarization 
reserve are already existing, including a dog model with chronic atrioventricular block [102]. 
Those animals, develop ventricular hypertrophy and bradycardia, and the IKs is consequently 
downregulated, which leads to a reduced repolarization reserve and increased arrhythmia 
susceptibility [102,103]. Acute pharmacological inhibition of IKs by HMR-1556 [66] can also 
imitate reduced repolarization reserve. Loss-of-function mutations in repolarizing and gain-
of-function mutations in depolarizing currents cause congenital long QT syndromes with 
impaired repolarization and increased risk of sudden death [104]. The two most common 
forms of congenital LQT (LQT1 and LQT2) were modelled by expression of human mutant 
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KCNQ1 and KCNH2 genes in transgenic rabbits in a landmark study by Brunner et al. [50]. A 
remarkable prolongation of the QT interval was observed in both LQT1 and LQT2, and LQT2 
transgenic rabbits showed a high incidence of sudden death [50,105]. These two transgenic 
rabbit models effectively express the human LQT1 and LQT2 phenotypes, and they are 
valuable tools to investigate the mechanisms of sudden cardiac death. On the other hand, it is 
also important to study  „silent‟ or „subclinical‟ LQT cases, where impairment of 
repolarization reserve does not necessarily result in clinically obvious QT-prolongation, but 
the heart is more susceptible to arrhythmia development. Here, we would like to introduce 
and characterize a novel transgenic rabbit model with hidden repolarization reserve 
complications, which do not necessarily  result in QT-prolongation, but the heart is more 
sensitive to arrhythmia development [101,106]. 
7.6 Effects of the G52R-KCNE1 mutation on repolarizing potassium currents in left 
ventricular myocytes, obtained from WT and LQT5-TG rabbit hearts. 
 
The amplitude of the IK1 current and the tail current of IKr and IKs were not different 
between the two groups. The isolation procedure might have an effect on the current 
amplitudes and densities, which may attenuate differences between study groups, even in 
relatively large numbers of rabbits (8–24) and cells (20–64). On the other hand, IKr/IKs 
deactivation kinetics were significantly affected in LQT5-TG rabbits, potentially accounting 
for the in vivo phenotype. The functional importance of the moderate augmentation of Ito in 
LQT5-TG rabbits is difficult to interpret, because in the rabbit heart the Ito is mainly, but not 
completely carried by the Kv 1.4 channels [17]. These channels recover slowly (>1s time- 
constant) from inactivation. Due to the fast heart rate of the rabbit (in the range of 200–250 
beats min
-1
), the possible contribution of Ito to the repolarization of the ventricle is 
questionable, while it might be broadly inactivated at normal heart rates. The faster 
deactivation kinetics of IKr and IKs currents in LQT5-TG animals compared to WT is the most 
important difference at cellular level. Due to the more rapid deactivation, the channels close 
faster and it results in lower densities of IKs and IKr during the action potential. According to 
those changes in kinetic parameters, the repolarization reserve is impaired, which might be a 
possible explanation behind the greater susceptibility of LQT5-TG rabbits to arrhythmias 
during in vivo studies. This faster deactivation of IKs in ventricular myocytes expressing the 
mutant G52R-KCNE1 gene contradicts with the observations in Xenopus oocytes, where the 
co-expression of the wild type KCNE1 and the G52-KCNE1 results in a 50% reduction in the 
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IKs current amplitude [51]. In CHO cells, co-expression of KCNQ1 with G52R-KCNE1 
produced a current devoid of the characteristic slow activation of IKs, and the current density 
was similar to those in cells expressing only KCNQ1 [53]. The possible explanation behind 
the controversial results in rabbit CM compared to expression systems is unknown. 
Nevertheless, there is growing evidence suggesting that other subunits such as KCNE2, 
KCNE3 and maybe KCNE4 and KCNE5 might interact with the KCNQ1, not only KCNE1 
[107,108]. In addition, although KCNE1 is established primarily as a KCNQ1 subunit, there 
is evidence that it may also play a role in IKr function [109–111]. The varying contributions of 
different accessory subunits may account for the different effects of mutations in different 
expression systems.  
7.7 The in vivo results show that LQT5-TG rabbits are sensitive to arrhythmia 
provocation 
 
There were no spontaneous sudden deaths in LQT5-TG animals during in vivo 
experiments. During ECG studies, a small, but significant prolongation of the heart rate-
corrected QT index could be observed in xylazine/ketamine-anaesthetized LQT5-TG rabbits, 
suggesting mild prolongation of repolarization (Figure 16). Contrasting with observations 
during anaesthesia with ketamine/xylazine, which does not affect repolarizing ion-currents 
[47], during thiopental-anaesthesia, there were no differences in the QT or frequency-
corrected QTc intervals between TG rabbits and their WT littermates. Thiopental can block 
IKs current [112], while xylazine/ketamine does not [113]. It seems that during thiopental 
anaesthesia, the minor baseline repolarization difference can perish. The short-term variability 
of the QT interval (which is an ECG biomarker for proarrhythmic risk [114,115]), was 
significantly larger in LQT5-TG rabbits (Figure 17 A,B and D) under thiopental anaesthesia, 
suggesting increased repolarization instability already at baseline. We used the selective IKr-
blocker dofetilide to compare the arrhythmia-susceptibility of LQT5-TG rabbits having 
reduced repolarization reserve with WT littermates. Dofetilide caused a marked prolongation 
in the QT interval in both groups and an additional increase of the STVQT in LQT5-TG 
rabbits. The drug also provoked typical drug-induced polymorphic ventricular tachycardia, 
TdP, in a greater number of LQT5-TG animals compared with WT (Figure 17E), and the 
duration of those episodes were significantly longer (Figure 17F). These observations agree 
with other proarrhythmia studies in models with reduced repolarization reserve, such as dogs 
with chronic AV-block [65] and anaesthetized rabbits subjected to pharmacological block of 
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IKs [66]. We were not able to see any evidence of cardiac structural or functional disorders in 
LQT5-TG rabbits. Further studies with echocardiographic assessment of cardiac structure are 
needed to exclude any subtle alterations occurring in the model. Additional experiments 
should be performed in the future to characterize the cellular electrophysiological mechanisms 
responsible for the increased arrhythmia susceptibility observed in LQT5-TG rabbits, 
especially in the light of data indicating that (i) chronic loss of function of one repolarizing 
current can lead to compensatory up-regulation of other K
+
-channels [116] and (ii) different 
KCNE-encoded proteins do not exclusively associate with KvLQT1 to form IKs channels, but 
may be involved in the assembly of other ion channels [117,118]. All the main ionic currents 
should be studied in a large number of native ventricular cardiomyocytes isolated from LQT5-
TG and WT rabbits at different voltage levels, focusing on kinetic properties of the channels. 
In addition, it would be interesting to create a study involving wild-type KCNE1 
overexpression, to compare the resulting phenotype with animals, which overexpress the 
mutant KCNE1. Furthermore, studies of the effects of additional repolarization-stresses, such 
as adrenergic stimulation, would be appropriate. Finally, it would be useful to examine 
whether changes occur in other ion-currents like INa and ICa,L, because they might be altered as 
part of the cellular adaptation to changes in electrical function induced by the mutation. 
7.8 Potential role of the two introduced models in the future 
 
In cardiovascular pharmacology it is very important to have reliable models, which 
reflect human heart physiology not only in undiseased, but also in diseased conditions. Both 
models introduced in this thesis have their own strengths and weaknesses, but their potential 
is large. 
The use of hiPSC-CM is a unique opportunity, because they are programmed from 
human cells, relatively easy to handle them, and provides a great opportunity to create 
diseased cell lines [27,28,36,86] and also to apply gene therapy such as the CRISPR/Cas9 
technique in vitro [32]. To improve the maturity of these cell lines is still a very important 
issue, and a detailed electrophysiological characterization is suggested even in the control cell 
lines, before using them for disease modelling. As shown in the first part of the thesis, the 
measured low RMP values might be due to technical problems, which are also important 
issues, so choosing the right approach during the studies is crucial. This technical issue is not 
that pronounced in native mature cardiomyocytes where the capacitance of the cells and the 
potassium conductance are high. On the other hand, several reports showed promising results  
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in case of structural and electrophysiological maturation [34,35,38,40], so there is no doubt 
that those cells will become important and standard tools for cardiovascular research in the 
future. 
Creating transgenic animals have also a great significance in cardiovascular 
pharmacology. Small rodents are commonly used to model various heart diseases, and those 
models can provide a platform not only for in vitro, but also for in vivo studies [42,119]. 
Studies in rodent models have greatly improved our knowledge about the mechanisms of 
arrhythmias. To overcome the reported differences in heart physiology in rodents, compared 
to human, there is a growing interest to use larger rodents such as rabbits for this purpose. The 
physiology of the rabbit heart is more similar to the human, and creation of transgenic rabbits 
which are modelling heart diseases was already successful, and showed great results [46–
48,62].  
Our LQT5-TG rabbit model is representing a very challenging clinical case called 
“silent” LQT. We are confident that this model provides an outstanding tool to understand not 
only the underlying mechanism of this disease, but also to develop new diagnostic approaches 
and potentially novel alternatives for the prevention and treatment of life threatening 
arrhythmias.  
In conclusion, both models may play a significant future role in cardiovascular research, 
and can increase our understanding in the underlying mechanisms of cardiac diseases. They 
also represent valuable platforms in the development and testing of novel, safe antiarrhythmic 
drugs in order to reduce the risk of sudden cardiac death.
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8 Conclusions and potential significance 
 
The conclusions and main findings of the present thesis are as follows: 
(a) HiPSC-CM can possess robust IK1 current densities, which, in ML, reached values of 
human LV-CM and, in EHT, that of RA-CM under identical experimental conditions.  
(b) Technical issues related to patch clamping of small cells probably contribute to the 
reported low RMP in hiPSC-CM. HiPSC-CM exhibit features of both an atrial (IK1 and RMP) 
and ventricular phenotype (absence of IK,ACh and low repolarization fraction). Low IK1 and 
depolarized RMP are not inherent characteristics of hiPSC-CM. 
(c) A novel LQT5-TG rabbit model based on the cardiac-specific overexpression of 
human KCNE1 carrying a G52R missense was successfully created. These rabbits exhibit 
reduced repolarization reserve, but no striking repolarization disturbances or serious 
ventricular arrhythmias at baseline. However, LQT5-TG rabbits are more susceptible to 
arrhythmias than WT littermates upon repolarization stress, indicating that they may be 
suitable to model the challenging clinical situation of „silent‟ LQT.  
(d) This model can also provide further insights into the mechanisms underlying 
arrhythmias and sudden cardiac death based on repolarization disturbances and may represent 
a novel model for testing the proarrhythmic potential of new drugs under development. 
      (e) Both models can be a reliable future tool for cardiovascular pharmacology and disease 
modelling studies in vitro and in vivo, because their large similarity to human heart. 
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